CDEK
← All drugs Report issue

oxaliplatin

Trade name: eloxatin

Small moleculeapprovedFast Track FDA

Approved

Aug 9, 2002

Oxaliplatin (brand name Eloxatin), a new generation of platinum derivatives discovered by Prof Kidani in 1976 at Nagoya University in Japan, was licensed-in and developed by Debiopharm. Eloxatin is typically administered in combination with fluorouracil and leucovorin for the adjuvant treatment of stage III colon cancer and for the treatment of advanced carcinoma of the colon or rectum. Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo 1,2-diaminocyclohexane (DACH) platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. — NCATS

Clinical trial activity

2,475 trials · 951 clinical orgs · 30 marketing orgs

Phase 1
471
Phase 2
2000
Phase 3
514
Phase 4
36

Earliest trial started Jan 1, 1998 (NCT00003260)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Aug 9, 2002

    Sanofi-Synthelabo — Earliest FDA Approval

  2. Aug 9, 2002

    Sanofi-Aventis — NDA Secondary Org

  3. Aug 9, 2002

    Sanofi-Synthelabo — NDA Organization

  4. Aug 7, 2009

    Teva — NDA Secondary Org

  5. Aug 7, 2009

    Hospira — Marketing Organization

  6. Aug 7, 2009

    Fresenius — Marketing Organization

  7. Aug 7, 2009

    Mustafa Nevzat Pharmaceuticals — Marketing Organization

  8. Aug 7, 2009

    Sandoz — Marketing Organization

  9. Aug 7, 2009

    Sun Pharmaceuticals — Marketing Organization

  10. Aug 7, 2009

    Novartis — Marketing Organization

2010s

  1. Jan 14, 2010

    Pliva — Marketing Organization

  2. Jan 14, 2010

    Teva — Marketing Organization

  3. Aug 7, 2012

    Mylan — Marketing Organization

  4. Aug 8, 2012

    Actavis — Marketing Organization

  5. Aug 8, 2012

    PHARMOBEDIENT — Marketing Organization

  6. Jun 18, 2014

    Hengrui Therapeutics, Inc. — Marketing Organization

  7. Jun 18, 2014

    Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. — Marketing Organization

  8. Jun 7, 2016

    Qilu Pharmaceutical Co., Ltd. — Marketing Organization

  9. Feb 10, 2017

    Cipla — Marketing Organization

  10. Feb 10, 2017

    Gland Pharma Ltd — Marketing Organization

  11. Feb 10, 2017

    Chartwell Pharmaceuticals — Marketing Organization

  12. Mar 21, 2017

    Accord Research — Marketing Organization

  13. May 12, 2017

    Sankyo — Marketing Organization

  14. May 12, 2017

    Lutipold — Marketing Organization

  15. May 12, 2017

    Daiichi Sankyo — Marketing Organization

  16. Sep 6, 2017

    Eugia Pharma — Marketing Organization

  17. Mar 5, 2018

    Allergan PLC (2015) — Marketing Organization

  18. Oct 16, 2018

    Ingenus Pharmaceuticals — Marketing Organization

  19. Oct 16, 2018

    Novast Labs — Marketing Organization

2020s

  1. Jan 11, 2024

    Meitheal — Marketing Organization

  2. Jan 27, 2025

    Hetero Labs Ltd — Marketing Organization

  3. Jan 15, 2026

    Shandong Lanjin Pharmaceuticals Co.,Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

Approval history

  • approvedPriority reviewAcceleratedFast trackAug 9, 2002

Chemistry & pharmacology

Loading structure…

SMILES

[Pt++].[O-]C(=O)C([O-])=O.N[C@@H]1CCCC[C@H]1N
Mol. weight
397.292 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • 1,2-diaminocyclohexane platinum oxalate
  • 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(ii)
  • act 078
  • act-078
  • amt2003
  • cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(ii)
  • diaminocyclohexane oxalatoplatinum
  • diaminocyclohexane oxalatoplatinum
  • eloxatin
  • eloxatin
  • eloxatin
  • eloxatin
  • eloxatin
  • eloxatine
  • folfirinox
  • folfox
  • folfox
  • folfox-4
  • folfox-4
  • jm-83
  • l-ohp
  • l-ohp
  • l-ohp
  • l-ohp cpd
  • l-plat
  • mbp-426
  • mbp-426
  • oxalato-(1,2-cyclohexanediamine)platinum ii
  • oxalatoplatin
  • oxalatoplatin
  • oxalatoplatinum
  • oxalatoplatinum
  • oxalatoplatinum
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatin
  • oxaliplatine
  • oxaliplatine
  • oxaliplatine
  • oxaliplatino
  • oxaliplatino
  • oxaliplatin, (sp-4-2-(1r-trans))-isomer
  • oxaliplatin, (sp-4-2-(1s-trans))-isomer
  • oxaliplatin, (sp-4-3-(cis))-isomer
  • oxaliplatinum
  • oxaliplatinum
  • oxapliplatin
  • platinum(ii)-1,2-cyclohexanediamine oxalate
  • rp-54780
  • sanofi brand of oxaliplatin
  • sanofi synthelabo brand of oxaliplatin
  • sr96669
  • sr-96669

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07283705Phase 2May 18, 2026Bristol-Myers Squibb, University of Texas at Houston
NCT07281768Phase 2Mar 31, 2026Johns Hopkins University, Regeneron
NCT07221149Phase 2/Phase 3 (Phase 3)Mar 9, 2026Biontech, Bristol-Myers Squibb
NCT07221357Phase 2/Phase 3 (Phase 3)Mar 4, 2026Biontech, Bristol-Myers Squibb
NCT07290985Phase 2Mar 1, 2026American Association for Cancer Research, Jazz Pharmaceuticals
NCT06978062Phase 1Feb 20, 2026European Organisation for Research and Treatment of Cancer, Johannes Gutenburg University, University of Mannheim, University of Oxford
NCT07284849Phase 3Feb 16, 2026Incyte
NCT07283848Phase 2Feb 1, 2026Arcus Biosciences, Inc., Gateway for Cancer Research, Harvard University
NCT07263360Phase 2Feb 1, 2026Tianjin Medical University
NCT07266025Phase 2Jan 30, 2026Fudan University
NCT07243938Phase 2Jan 15, 2026Huazhong University of Science and Technology
NCT07113275Phase 3Jan 1, 2026Huazhong University of Science and Technology
NCT07239466Phase 2Jan 1, 2026Huazhong University of Science and Technology
NCT07298772Phase 1/Phase 2 (Phase 2)Dec 31, 2025Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07146646Phase 2Dec 31, 2025Case Western Reserve University, National Comprehensive Cancer Network
NCT07229846Phase 2Dec 31, 2025Harbin Medical University
NCT06783491Phase 3Dec 31, 2025Spanish Association of Surgeons (AEC), Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Universidad de Cordoba
NCT07150403Phase 2Dec 31, 2025Federation Francophone de Cancerologie Digestive
NCT07238283Phase 3Dec 31, 2025Hengrui Therapeutics, Inc.
NCT07255404Phase 2Dec 31, 2025Biontech, Bristol-Myers Squibb
Showing 20 of 2,475 trials
Page 1 / 124

Organizations

Research & Development (951)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government2379551998
Sun Yat-Sen UniversityAcademic/Hospital14313542010
Fudan UniversityAcademic/Hospital13311052005
SanofiFor profit1264151998
RocheFor profit954442003
Chinese Academy of Medical SciencesAcademic/Hospital886842005
Zhejiang UniversityAcademic/Hospital604952010
Jiao Tong UniversityAcademic/Hospital543752004
University of Texas at HoustonAcademic/Hospital463432000
GenentechFor profit441442003
Peking UniversityAcademic/Hospital433352008
Nanjing Medical UniversityAcademic/Hospital413352009
Fujian Medical UniversityAcademic/Hospital383342016
Harvard UniversityAcademic/Hospital383132000
People's Liberation Army of ChinaGovernment373142004
Bristol-Myers SquibbFor profit34842003
MerckFor profit331632004
UNICANCERAcademic/Hospital312721999
AmgenFor profit291132004
University of UlsanAcademic/Hospital272132004
951 organizations
Page 1 / 48

Marketing (41)

OrganizationOrg typeRelationshipDate
Accord ResearchFor profitMKTGMar 21, 2017
ActavisFor profitSYNMar 5, 2018
ActavisFor profitMKTGAug 8, 2012
ActavisFor profitSYNMar 5, 2018
Allergan PLC (2015)For profitMKTGMar 5, 2018
Chartwell PharmaceuticalsFor profitMKTGFeb 10, 2017
CiplaFor profitMKTGFeb 10, 2017
Daiichi SankyoFor profitMKTGMay 12, 2017
Eugia PharmaFor profitMKTGSep 6, 2017
FreseniusFor profitMKTGAug 7, 2009
FreseniusFor profitSYNJun 2, 2010
Gland Pharma LtdFor profitMKTGFeb 10, 2017
Gland Pharma LtdFor profitMKTGFeb 10, 2017
Hengrui Therapeutics, Inc.For profitMKTGJun 18, 2014
Hengrui Therapeutics, Inc.For profitSYNJun 18, 2014
Hetero Labs LtdFor profitMKTGJan 27, 2025
HospiraFor profitSYNSep 30, 2009
HospiraFor profitMKTGAug 7, 2009
Ingenus PharmaceuticalsFor profitMKTGOct 16, 2018
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.For profitMKTGJun 18, 2014
LutipoldFor profitMKTGMay 12, 2017
MeithealFor profitMKTGJan 11, 2024
Mustafa Nevzat PharmaceuticalsFor profitMKTGAug 7, 2009
MylanFor profitMKTGAug 7, 2012
NovartisFor profitMKTGAug 7, 2009
Novast LabsFor profitMKTGOct 16, 2018
PHARMOBEDIENTFor profitMKTGAug 8, 2012
PlivaFor profitMKTGJan 14, 2010
Qilu Pharmaceutical Co., Ltd.For profitSYNMay 11, 2016
Qilu Pharmaceutical Co., Ltd.For profitMKTGMay 11, 2016
Qilu Pharmaceutical Co., Ltd.For profitMKTGJun 7, 2016
SandozFor profitSYNJan 24, 2011
SandozFor profitMKTGAug 7, 2009
SankyoFor profitMKTGMay 12, 2017
Sanofi-AventisFor profitNDA2Aug 9, 2002
Sanofi-SynthelaboFor profitNDAAug 9, 2002
Shandong Lanjin Pharmaceuticals Co.,LtdFor profitMKTGJan 15, 2026
Sun PharmaceuticalsFor profitSYNAug 7, 2009
Sun PharmaceuticalsFor profitMKTGAug 7, 2009
TevaFor profitNDA2Aug 7, 2009
TevaFor profitMKTGJan 14, 2010